JPMorgan upgraded Kodiak Sciences (KOD) to Overweight from Neutral with a price target of $24, up from $15. The firm believes the company’s KSI-101 in macular edema secondary to inflammation is “de-risked” and could drive upside in the shares as the opportunity is better appreciated by the market. Data from the Phase 3 PEAK and PINNACLE studies of KSI-101 are anticipated in Q4 of 2026 and Q1 of 2027, respectively, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- JPMorgan healthcare analysts hold an analyst/industry conference call
- Kodiak Sciences initiated with an Outperform at LifeSci Capital
- Kodiak Sciences upgraded to Equal Weight from Underweight at Barclays
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz
- Promising Drug Pipeline and Strong Financial Position Drive Buy Rating for Kodiak Sciences